Dominantly Inherited Alzheimer Network (DIAN) (NCT00869817)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (26 Sites)

Showing the first 25 of 26 sites.

• Mayo Clinic Jacksonville — Jacksonville, Florida
• Indiana University-Indiana Alzheimer Disease Center — Indianapolis, Indiana
• Brigham and Women's Hospital — Boston, Massachusetts
• Washington University in St. Louis School of Medicine — St Louis, Missouri
• Columbia University — New York, New York
• University of Pittsburgh — Pittsburgh, Pennsylvania
• Butler Hospital — Providence, Rhode Island
• University of Washington — Seattle, Washington
• Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) — Salta, Salta Province
• Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia" (FLENI) Instituto de Investigaciones Neurológicas Raúl Correa — Buenos Aires,
• Neuroscience Research Australia — Sydney, New South Wales
• Mental Health Research Institute, University of Melbourne — Melbourne, Victoria
• Sir James McCusker Alzheimer's Disease Research Unit, Edith Cowan University — Perth, Western Australia
• Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo — São Paulo, São Paulo
• McGill University Research Centre for Studies in Aging — Verdun, Quebec
• Grupo Neurociencias de Antioquia — Medellín, Colombia
• German Center for Neurodegenerative Diseases (DZNE) Munich, and University Hospital Ludwig-Maximilians-Universitat (LMU) Munich — Munich,
• German Center for Neurodegenerative Diseases (DZNE) Tübingen and Hertie-Institute for Clinical Brain Research, University of Tübingen — Tübingen,
• Niigata University — Niigata,
• Osaka City University — Osaka,
• Tokyo University — Tokyo,
• Instituto Nacional de Neurología y Neurocirugía "Manuel Velasco Suarez" — Mexico City, Mexico City
• Amsterdam UMC — Amsterdam,
• Asan Medical Center — Seoul, Songpa-Gu
• Hospital Clinic Barcelona — Barcelona, Catalonia

📞 Contact the Study Coordinator

Phone: (314) 273-9057

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Alzheimer's Disease

• Standardizing Care for Neuropsychiatric Symptoms and Quality of Life in Dementia — Calgary, Alberta
• A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology — Clermont, Florida
• A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease — Phoenix, Arizona
• DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease — Birmingham, Alabama
• A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) — Birmingham, Alabama
• A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) — Chandler, Arizona

Explore by condition: All Alzheimer's Disease clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.